By MAAYAN JAFFE-HOFFMAN
Double-blind study shows ivermectin reduces disease’s duration and infectiousness • FDA and WHO caution against its use
- Approx. 72% of the Ivermectin group tested negative and 13% were infectious after day six
- 50% of the placebo group tested positive and 50%, almost 4 times as many, were infectious after day six
- 5 patients were referred to hospitals, 4 of them were in the placebo group
- One hospitalized patient complained of shortness of breath, continued on ivermectin and was sent back to the hotel a DAY later in good condition
“Our study shows first and foremost that ivermectin has antiviral activity,” Schwartz said. “It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact.”
- 27 studies demonstrate ivermectin’s ability to prevent COVID
- a recent review found ivermectin reduced death by 75%
Researchers in other places worldwide began looking into the drug at around the same time. But when they started to see positive results, no one wanted to publish them, Schwartz said.
“There is a lot of opposition,” he said. “We tried to publish it, and it was kicked away by three journals. No one even wanted to hear about it. You have to ask how come when the world is suffering.”
“This drug will not bring any big economic profits,” and so Big Pharma doesn’t want to deal with it, he said.